Healthcare
Novo Nordisk A/S(NONOF)
Live Price
Offline$43.40
-1.39% today
1Y Change
-28.11%
Window
Jun 26, 2025 β Jun 24, 2026
- Market Cap
- $1.24T
- Revenue Growth
- +6.2%
- EPS Growth
- +1.4%
- Dividend Yield
- 4.2%
Coverage: 250 bars Β· Jun 26, 2025 β Jun 24, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Novo Nordisk A/S (NONOF) is a Healthcare stock with a market cap of $1.24T and listed on OTC. The stock last traded around $43.40 and down 28.1% across the available one-year price window (Jun 26, 2025 β Jun 24, 2026). Baseline metrics include revenue growth of +6.2%, EPS growth of +1.4%, a dividend yield of 4.2%. What stands out right now is revenue +6.2%, EPS +1.4%, free cash flow -15.5% with operating margin 41.3% and ROIC 29.5%. The dividend matters to the case here, with a current yield around 4.2%. Valuation is more restrained than many high-expectation growth names at P/E 12.1 and price/sales 4.0. Overall, the current profile looks closer to a income-oriented value setup than a generic broad-market placeholder. Stock Foundry combines NONOF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+6.2% vs +7.6% peer median
Operating Margin
Above sector median
+41.3% vs +19.4% peer median
P/E
Below sector median
12.1 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +6.2% and EPS at +1.4%, with operating margin around 41.3%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 4.2%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -0.4% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | β | -1.4% | -0.8% | -4.0% |
2026 Feb 3, 2026 | +2.8% | -5.6% | -1.0% | -23.0% |
2025 Nov 5, 2025 | -7.9% | -4.0% | +0.5% | -4.6% |
Benchmark Edge
NONOF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NONOF
β
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NONOF Max Drawdown
-50.04%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for NONOF and SPY.
Company Overview
Novo Nordisk A/S
Other OTC
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
- Leadership
- Maziar Mike Doustdar
- IPO Date
- May 7, 2010
- Employees
- 77.4k
- Street Address
- Novo AllΓ© 1
- Mailing
- Bagsvaerd, 2880
- Region
- Bagsvaerd, DK
- Reporting Currency
- USD
- Investor Line
- 45 44 44 88 88
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 12.1
- EV/EBITDA
- 8.3
- Price/Sales
- 4.0
- Price/Book
- 6.4
Growth
- Revenue
- +6.2%
- EPS
- +1.4%
- Free Cash Flow
- -15.5%
Profitability
- Gross Margin
- 81.0%
- Operating Margin
- 41.3%
- Net Margin
- 33.1%
- ROE
- 61.1%
- ROIC
- 29.5%
Balance Sheet
- Debt/Equity
- 0.67
- Current Ratio
- 0.80
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.